KAND567 is a small molecule treatment which blocks the fractalkine receptor involved when the immune system starts an exaggerated inflammatory response. This prevents damaging immune cells ...
Kancera signs letter of intent agreement with US biotech company, Recardio Inc., with the intention to out-license its fractalkine program, including drug candidates KAND567 and KAND145Recardio's phas ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback